Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 503 | 48 | 449 |
| Samples | 175 | 26 | 147 |
| Peptides | 126 | 18 | 108 |
Function
KLK7 · Kallikrein related peptidase 7
This gene encodes a member of the kallikrein subfamily of serine proteases. These enzymes have diverse physiological functions and many kallikrein genes are biomarkers for cancer. The encoded protein has chymotrypsin-like activity and plays a role in the proteolysis of intercellular cohesive structures that precedes desquamation, the shedding of the outermost layer of the epidermis. The encoded protein may play a role in cancer invasion and metastasis, and increased expression of this gene is associated with unfavorable prognosis and progression of several types of cancer. Polymorphisms in this gene may play a role in the development of atopic dermatitis. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene, which is one of fifteen kallikrein subfamily members located in a gene cluster on chromosome 19. [provided by RefSeq, May 2011].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 121 amino-acid changes on canonical ENST00000595820 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KLK7 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KLK7 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Melanoma | 2/210 1% | 41/1899 2% |
| Endometrial Carcinoma | 0/42 0% | 10/612 2% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 11/1390 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Other Solid Cancers | 0/94 0% | 9/1515 1% |
| Colorectal Carcinoma | 2/143 1% | 15/3239 0% |
| Gastric Carcinoma | 2/74 3% | 7/1809 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| Hepatocellular Carcinoma | 2/46 4% | 6/2210 0% |
| Prostate Carcinoma | 0/13 0% | 5/2105 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 4/2550 0% |
| B-Lymphoblastic Leukemia | 3/55 5% | 1/2640 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 1/810 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Bladder Carcinoma | 0/58 0% | 1/956 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 0/2534 0% |
| Other Blood Cancers | 0/61 0% | 2/2725 0% |
| Breast Carcinoma | 0/144 0% | 2/3264 0% |
Mutation Distribution
Where KLK7 is mutated · all tissues, split by cell line vs tissue
How many mutations in KLK7 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 503 mutations in KLK7
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|